Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 30, 2023New England Journal of Medicine

Mezigdomide and Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJake Shortt

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jake Shortt (2023) studied this question.

synapsesocial.com/papers/6a1f3752d09bc027e483300ahttps://doi.org/10.1056/nejme2307370
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells2013 · 1,887 citations
  2. 2Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma2023 · 91 citations
  3. 3Identification of a Primary Target of Thalidomide Teratogenicity2010 · 2,136 citations
  4. 4IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos2018 · 91 citations
  5. 5Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma2020 · 229 citations